BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panchal H, Wagner M, Chatterji M, Taouli B, McBride R, Patterson JR, Ungaro R, Dubinsky M, Cho J, Sachar DB. Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage. Dig Dis Sci 2019;64:3274-83. [PMID: 30607690 DOI: 10.1007/s10620-018-5434-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhu M, Feng Q, Xu X, Qiao Y, Cui Z, Yan Y, Ran Z. Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index. BMC Gastroenterol 2020;20:421. [PMID: 33308166 DOI: 10.1186/s12876-020-01575-7] [Reference Citation Analysis]
2 D’amico F, Pugliese N, Peyrin-biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2020;14:347-53. [DOI: 10.1080/17474124.2020.1759417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Krusiński A, Grzywa-Celińska A, Szewczyk K, Grzycka-Kowalczyk L, Emeryk-Maksymiuk J, Milanowski J. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam 2021;2021:6284987. [PMID: 33489084 DOI: 10.1155/2021/6284987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rodríguez-lago I, Gisbert JP. The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn’s Disease. Journal of Crohn's and Colitis 2020;14:557-66. [DOI: 10.1093/ecco-jcc/jjz158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
5 Sparrow MP. Quantification of Digestive Disease Damage in Crohn's Disease, Are We There Yet With the Lémann Index? Gastroenterology 2021;161:800-2. [PMID: 34175282 DOI: 10.1053/j.gastro.2021.06.047] [Reference Citation Analysis]
6 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
7 Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021;160:1452-1460.e21. [PMID: 33421515 DOI: 10.1053/j.gastro.2020.10.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Italia A, Morino M, Saracco GM, Astegiano M. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index. Scandinavian Journal of Gastroenterology 2019;54:1339-45. [DOI: 10.1080/00365521.2019.1686057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Le Berre C, Danese S, Peyrin-biroulet L. Timely Use of Biologics in Early Crohn’s Disease: The Return of “Hit Hard and Early”? Dig Dis Sci 2019;64:3035-7. [DOI: 10.1007/s10620-019-05504-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
11 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther 2021. [PMID: 34881439 DOI: 10.1111/apt.16723] [Reference Citation Analysis]
13 Rodríguez-Lago I, Zabana Y, Barreiro-de Acosta M. Diagnosis and natural history of preclinical and early inflammatory bowel disease. Ann Gastroenterol 2020;33:443-52. [PMID: 32879589 DOI: 10.20524/aog.2020.0508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]